Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase I Trial of Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Sponsor: University of Colorado, Denver
Terminated
Low enrollment, University Scientific Review Committee required study closure.
Other terminated trials from University of Colorado, Denver
Other Acute Myeloid Leukemia trials with similar outcome
A PHASE1 clinical study on Acute Myeloid Leukemia and Relapsed/Refractory Acute Myeloid Leukemia, this trial is terminated or withdrawn. The trial is conducted by University of Colorado, Denver and has accumulated 12 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE1
Status: Completed → Terminated
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE1
-
May 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Mar 2021 — May 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Oct 2019 — Aug 2020 [monthly]
Recruiting PHASE1
-
Aug 2018 — Oct 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2017 — Feb 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Colorado, Denver
For direct contact, visit the study record on ClinicalTrials.gov .